CT-388
ZYNERGY
Roche · Phase 2 · Not yet recruiting · Enrollment 486
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Arm 1: Petrelintide + Enicepatide Dosing Regimen 1 | n/r | n/r | n/r | n/r | n/r |
| Arm 2: Petrelintide + Enicepatide Dosing Regimen 2 | n/r | n/r | n/r | n/r | n/r |
| Arm 3: Petrelintide + Enicepatide Dosing Regimen 3 | n/r | n/r | n/r | n/r | n/r |
| Arm 4: Petrelintide-matching Placebo + Enicepatide | n/r | n/r | n/r | n/r | n/r |
| Arm 5: Petrelintide + Enicepatide-matching Placebo | n/r | n/r | n/r | n/r | n/r |
| Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.